<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973752</url>
  </required_header>
  <id_info>
    <org_study_id>08-356</org_study_id>
    <nct_id>NCT00973752</nct_id>
  </id_info>
  <brief_title>Treatment of Older Adults With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Treatment of Older Adults With Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enzon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of a multi-drug
      regimen (which includes prednisone, vincristine, cytarabine, doxorubicin, 6 mercaptopurine,
      and methotrexate) which is considered standard treatment for children and young adults with
      acute lymphoblastic leukemia (ALL), in combination with PEG-asparaginase and clofarabine to
      treat older adults with ALL. PEG-asparaginase has been used in chemotherapy treatment
      regimens for both children and adults with ALL. Clofarabine has been used in chemotherapy
      treatment regimens for children with ALL and has been shown to decrease the number of
      leukemia cells. Participants with leukemia that has an abnormal chromosome, called the
      Philadelphia chromosome, will also be given imatinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This research study has stages of treatment as follows: 1) Induction 2) Consolidation 1
           3) Stem cell of Bone Marrow Transplant (if the participant is eligible). If the
           participant does not have a transplant: 4) CNS Therapy 5) Consolidation 2 6)
           Continuation Therapy.

        -  During all phases of study treatment, participants will have additional tests and
           procedures to monitor their health and for research purposes. These tests will include:
           physical exams, blood tests, bone marrow aspirate/biopsy and EKGs (electrocardiogram)
           and/or ECHOs (echo-cardiogram).

        -  INDUCTION STAGE: This stage lasts for about one month. The study drugs and the way they
           are administered are as follows: Prednisone orally on days 1-21 for participants less
           than 60 and days 1-7 for participants 60 or greater; Vincristine intravenously on days
           1, 8, 15 and 22; Doxorubicin intravenously on days 1 and 2; PEG-Asparaginase
           intravenously on days 7 and 21; Cytarabine intrathecally on day 1; Methotrexate
           intrathecally on day 29; Imatinib orally on days 14-29 if participant has the
           Philadelphia Chromosome.

        -  After induction, if there is evidence of ALL in the spinal fluid, participants may need
           to receive more intrathecal therapy.

        -  CONSOLIDATION 1 Therapy: This stage will last about one month. Participants will receive
           Consolidation 1 Therapy, regardless of whether or not their ALL is in full remission
           after Induction. The study drugs and the way they are administered are as follows:
           Prednisone orally days 1-5; Clofarabine intravenously days 1-5; PEG-Asparaginase
           intravenously days 1 and 15; Imatinib continues orally for participants with the
           Philadelphia Chromosome.

        -  After the participants blood counts return to normal, their bone marrow will be tested.
           If the bone marrow shows remission, participants will proceed to the next stage of the
           study. If the bone marrow does not show remission, the participants will no longer
           continue on this study.

        -  STEM CELL or BONE MARROW TRANSPLANTATION: The next stage is stem cell or bone marrow
           transplantation if the participant is eligible. If the participant receives a stem cell
           transplant, they will receive additional chemotherapy (separate from the study drugs)
           followed by an infusion of stem cells. If the participant receives a bone marrow
           transplant, they will have a bone marrow aspirate and biopsy 3 months after the
           transplant and 12 months from the start fo the induction to monitor the status of the
           ALL. If the participant receives a bone marrow or stem cell transplant, they will
           continue to be a part of the study, but will not proceed with CNS Therapy, Consolidation
           2 Therapy, and Continuation Therapy.

        -  CENTRAL NERVOUS SYSTEM (CNS) THERAPY: CNS therapy will begin between 2 and 6 weeks
           following the end of Consolidation 1. This stage will last about one month. The study
           drugs and the way they are administered are as follows: vincristine intravenously on day
           1; doxorubicin intravenously on day 1; 6 mercaptopurine orally on days 1-14; prednisone
           orally on days 1-5; PEG-asparaginase intravenously on days 1 and 15;
           methotrexate/cytarabine/prednisone intrathecally weekly for 3 weeks; imatinib orally
           continues daily if the participant has the Philadelphia Chromosome.

        -  Radiation therapy will also be given during this stage of the participant is under 60
           years old. The purpose of radiation therapy is to prevent ALL from coming back in the
           brain. Radiation will be given in 8 treatments, given once a day, and will be scheduled
           with other study treatment.

        -  CONSOLIDATION 2 THERAPY: This stage begins as soon as CNS Therapy ends and lasts about 8
           months. Participants will receive repeated cycles of the study drug treatment about
           every 4 weeks. The study drugs and the way they are administered are as follows:
           vincristine intravenously on day 1; doxorubicin intravenously on day 1; 6 mercaptopurine
           orally on days 1-14; prednisone orally days 1-5; PEG-asparaginase orally on days 1 and
           15 (first cycle only); imatinib orally continues daily if the participant has
           Philadelphia chromosome.

        -  CONTINUATION THERAPY: This stage begins at the end of Consolidation 2 Therapy. The goal
           of this stage is to get rid of all of the ALL in the body. Participants will receive
           repeated cycles of the study drug treatment every 4 weeks. It will last until the
           participant has been in remission for 2 years. The study drugs and the way they are
           administered are as follows: vincristine intravenously on day 1; mercaptopurine orally
           on days 1-14; prednisone orally on days 1-5; methotrexate intravenously on day 15;
           imatinib orally continues daily if the participant has Philadelphia chromosome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival at One Year</measure>
    <time_frame>1 years</time_frame>
    <description>The number of participants alive one year after baseline.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients treated on same arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Intravenously during Induction, CNS, and Consolidation 2 therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-asparaginase</intervention_name>
    <description>Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Intrathecally during Induction and CNS therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Intrathecally during Induction, CNS, and Continuation Therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Intravenously during Consolidation 1 Therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 Mercaptopurine</intervention_name>
    <description>Orally during CNS, Consolidation 2 and Continuation Therapy</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lymphoblastic leukemia, excluding known mature B-cell ALL by the presence of any
             of the following: surface immunoglobulin, L3 morphology, t(8;14)(q24;q32), t(8;22), or
             t(2;8).

          -  Patients with mature B-cell ALL will be removed from the protocol as soon as the
             diagnosis is made and should be treated on a B-cell leukemia protocol.

          -  Patients with lymphoblastic lymphoma are also eligible

          -  No prior anti-leukemic therapy except &lt;1 week of steroids, and/or emergent radiation
             therapy to the mediastinum, or hydroxyurea or emergent leukopheresis. Longer steroid
             use for diseases other than leukemia is permitted.

          -  Age 51-75 years

          -  Ejection fraction &gt; 45%

          -  Creatinine &lt; 2.0 mg/dl

          -  Total bilirubin &lt; 3.0 mg/dl

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, 2

          -  Non-pregnant and non lactating

        Exclusion Criteria:

          -  Known HIV positive

          -  Comorbid medical condition, in the investigator's opinion, would make participation in
             this trial and adherence to the protocol guidelines difficult

          -  Active psychiatric or mental illness making informed consent or careful clinical
             follow-up unlikely
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Fathi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <results_first_submitted>December 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2017</results_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Amir Fathi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>All patients treated on same arm
Prednisone: Orally during Induction, Consolidation 1, CNS (central nervous system), Consolidation 2, and Continuation therapy.
Vincristine: Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
Doxorubicin: Intravenously during Induction, CNS, and Consolidation 2 therapy
PEG-asparaginase: Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
Cytarabine: Intrathecally during Induction and CNS therapy
Methotrexate: Intrathecally during Induction, CNS, and Continuation Therapy
Imatinib: Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
Clofarabine: Intravenously during Consolidation 1 Therapy
6 Mercaptopurine: Orally during CNS, Consolidation 2 and Continuation Therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>All patients treated on same arm
Prednisone: Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
Vincristine: Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
Doxorubicin: Intravenously during Induction, CNS, and Consolidation 2 therapy
PEG-asparaginase: Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
Cytarabine: Intrathecally during Induction and CNS therapy
Methotrexate: Intrathecally during Induction, CNS, and Continuation Therapy
Imatinib: Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
Clofarabine: Intravenously during Consolidation 1 Therapy
6 Mercaptopurine: Orally during CNS, Consolidation 2 and Continuation Therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="51" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>White blood cell count</title>
          <units>10^3 cell per μL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" lower_limit="0.7" upper_limit="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance status</title>
          <description>Eastern Cooperative Oncology Group Performance Status 0 Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature
Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours
Completely disabled; cannot carry on any self-care totally confined to bed or chair
Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chromosomal alterations</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Philadelphia chromosome positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed lineage leukemia rearrangement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunophenotype</title>
          <description>acute lymphoblastic leukemia (ALL) immunophenotype</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>B-cell ALL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-cell ALL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival at One Year</title>
        <description>The number of participants alive one year after baseline.</description>
        <time_frame>1 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>All patients treated on same arm
Prednisone: Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
Vincristine: Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
Doxorubicin: Intravenously during Induction, CNS, and Consolidation 2 therapy
PEG-asparaginase: Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
Cytarabine: Intrathecally during Induction and CNS therapy
Methotrexate: Intrathecally during Induction, CNS, and Continuation Therapy
Imatinib: Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
Clofarabine: Intravenously during Consolidation 1 Therapy
6 Mercaptopurine: Orally during CNS, Consolidation 2 and Continuation Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at One Year</title>
          <description>The number of participants alive one year after baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>All patients treated on same arm
Prednisone: Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
Vincristine: Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
Doxorubicin: Intravenously during Induction, CNS, and Consolidation 2 therapy
PEG-asparaginase: Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
Cytarabine: Intrathecally during Induction and CNS therapy
Methotrexate: Intrathecally during Induction, CNS, and Continuation Therapy
Imatinib: Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
Clofarabine: Intravenously during Consolidation 1 Therapy
6 Mercaptopurine: Orally during CNS, Consolidation 2 and Continuation Therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/ gr. 3/4 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Infection – other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Anemia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Hypertension</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 hypotension</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 anorexia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 colitis</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 constipation</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 diarrhea</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 stomatitis</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 nausea</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 taste alteration</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 vomiting</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 Abdominal pain</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 fatigue</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 Insomnia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 weight loss</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 Edema</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 hypoalbuminemia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 weakness</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 mental status change</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 back pain</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 pain, other</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 transaminitis</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 Elevated alkaline phosphatase</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperbilirubinemia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Allergic reaction</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 2 febrile neutropenia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 Infection</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 hyperglycemia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 hypocalcemia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 neuropathy</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 azotemia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 ureteral obstruction</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 dyspnea</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 hypoxia</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 erythema multiforme</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 pruritis</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 rash</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Grade 2 decubitus ulcer</sub_title>
                <description>Grade 1 toxicities were not required to be reported per protocol</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amir Fathi</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-1124</phone>
      <email>afathi@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

